Chemoprevention of Cancer

This volume contains part of the papers given at the second annual conference of the newly founded International Society of Cancer Chemoprevention held in August 1997 in St. Gallen, Switzerland. Pharmacologic intervention in human carcinogenes is in its very infancy, and internationally coordinated efforts to fight the evolution of human cancers are only now taking shape. This is one of the first efforts to unite experts of all major groups and centers worldwide in the highly fascinating and thought-provoking field of chemoprevention of cancer, especially of the breast, colon and prostate.

Klappentext

Pharmacologic interventions to prevent the evolution of human cancers are still in its infancy, although a good number o- mostly controlled - clinical studies have been performed in the past two decades. However, regarding the partially stagnating therapeutic results of major epithelial cancer types such as breast-, lung-, colon- and ENT-cancer types, the problem of in­ terference with the evolution of disease at a preclinical level is an intriguing one, and the field seems to develop into one of the fastest growing domaines of modern oncology. This process is fa­ cilitated by the developments of molecular on co-genetics and the gowing existence of family cancer units, allowing to better identi­ fy and inform respective high risk groups, thus enabling re­ searchers and clinicians to more realistically target their chemo­ preventive efforts to the true populations at risk. On this changing background, the newly formed International Society of Cancer Chemoprevention (ISCaC) together with the Swiss Cancer League and the Interdisciplinary Oncology Center of St. Gallen/Switzerland organized an international Symposium in September 1997, inviting basic researchers, epidemiologists and clinical oncologists of related disciplines to discuss pertinent issues of experimental and clinical chemo- and bio-prevention in a scientific workshop.

Inhalt

Smoking, Genetics and Cancer.- Is there a Genetic Basis for Lung Cancer Susceptibility?. Chemoprevention of Head and Neck and Lung (Pre)Cancer. Targets and Markers for Cancer Prevention.- Rationale and Mechanisms of Cancer Chemoprevention. Metabolic Targets of Cancer Chemoprevention: Interruption of Tumor Development by Inhibitors of Arachidonic Acid Metabolism. Identification of Meaningful High Risk Groups for Cancer Chemoprevention.- Prognostic Implications of Cancer Susceptibility Genes: Any News?. Identification of the Woman at Risk for Breast Cancer: Problem Solved?. Development of a New Prevention Maintenance Therapy. Clinical Cancer Chemoprevention.- Chemoprevention of Colorectal Cancer. Chemoprevention of Human Cancer: A Reasonable Strategy?.